Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... FREMONT, Calif. , April 1, 2015  ValGenesis ... Software solutions, announced today that it has completed its ... Section 101, Attest Engagements (AICPA, Professional Standards) for the ... 31 st 2014.  ... The ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Blood Screening Market by ... Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product ... - Forecasts to 2019 " report to ... is expected to reach $2.55 billion by 2019 ...
(Date:4/1/2015)... DALLAS and NEW YORK ... Biopharmaceuticals, Inc. (NASDAQ:  PTBI), a biopharmaceutical company advancing ... today provided an overview of the Company,s 2014 ... highlighted achievements below demonstrate the progress the Company ... with multiple corporate partnerships for its MuGard programs, ...
(Date:4/1/2015)... Los Angeles, CA (PRWEB) April 01, 2015 ... in fat loss, a multi-billion dollar industry. Founder of Fasciology, ... to target an area of fat, instead of having to ... science fiction. Black claims that “ prior to fat cooling ... commonly called sculpting or contouring, was liposuction, which is a ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3
... THOROLD, ON, Oct. 15 /PRNewswire/ - Norgen Biotek ... advancing powerful,tools for nucleic acids and protein purification, ... the isolation of nucleic acids from,environmental samples, the ... Kit. These kits are ideal for environmental microbiological,studies, ...
... Baxa is promoting its new PadLock Set Saver product ... Salt Lake City,UT, at The Salt Palace, October 15-17, ... is promoting,its new PadLock Set Saver at the ANCC ... aseptic IV administration set storage,solution, PadLock provides a secure ...
... OLDSMAR, Fla., Oct. 15 Cryo-Cell,International, Inc. (OTC ... largest and most established family cord blood banks, ... months ended August 31,2008., Consolidated revenues for ... approximately $4.6 million for the third quarter of,2007. ...
Cached Biology Technology:High-quality DNA/RNA from Microorganisms in Environmental Samples 2Baxa Corporation Features PadLock(R) Set Saver at the ANCC National Magnet Conference(TM) 2Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 2Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 3Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 4Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 5Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 6
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... 2013 Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ), ... the medical and retail industries, announced that their patented software ... means to meet the priorities spelled out by the US ... United States Attorneys titled, "Guidance Regarding Marijuana ...
... flatworms have the remarkable ability to regrow any missing body ... the molecular basis of regeneration. Over the ... differ depending on the severity of the injury they suffer. ... wound reacts at the cellular and molecular levels quite differently ...
... to the origin of species as "that mystery of mysteries," ... cannot fully explain how new animals and plants arise. ... based on the assumption that the main cause of the ... formation of barriers to reproduction between populations. Those barriers ...
Cached Biology News:Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 2Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 3Tissue loss triggers regeneration in planarian flatworms 2Long-held assumption about emergence of new species questioned 2Long-held assumption about emergence of new species questioned 3
... at the 3, 3', 4, and 4' ... an internal standard for the quantification of ... spectrometry. PGE2 is one of the primary ... of the most widely investigated prostaglandins. Its ...
Request Info...
Request Info...
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Biology Products: